Erbitux
(Cetuximab)Phase 3Monoclonal antibody
Cetuximab is used to treat certain types of cancer, including colorectal cancer and head and neck cancer, by blocking a protein that helps cancer cells grow.[1] Erbitux is currently being investigated across 106 indications[3], with its most advanced program in Phase 3.[1]
Erbitux is one of 1378 small molecule programs targeting Glioma. It is currently in Phase 3.
106
Indications
826
Total Trials
33
Active Trials
1,377
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Showing 10 of 106 indications
Competition
Competitive Landscape
2828 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Erbitux
IImclone
Phase 3
Nolvadex
SSan Diego Pacific Oncology & Hematology Associates
Preclinical
Prolia
AmgenPreclinical
Voltaren
NovartisPreclinical
Spravato
WWim Janssens
Preclinical
Cortef
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Vfend
PPrism Pharmaceuticals
Preclinical
Apatinib Mesylate
BBukwang Pharmaceutical
Preclinical
Diuretic
RReprieve Cardiovascular, Inc
Preclinical
Perflutren Lipid Microsphere
IImaRx Therapeutics
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Colorectal Cancer21 trials
Show 18 more trials
Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer With Liver Metastases or Lung Metastases That Are Potentially Removable by Surgery
Unknown status·—·Phase 2·NCT00513266·35 enrolled
Colorectal Cancer (CRC) Cetuximab Elderly Frail
Terminated·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT01522612·5 enrolled
Metastatic Colorectal Cancer17 trials
Show 14 more trials
Phase II Study to Evaluate Safety and Efficacy of Cetuximab in Combination With XELOX for 12 Weeks Followed by Maintenance Treatment With Cetuximab Plus Capecitabine as First-line Treatment in Elderly Patients With Metastatic Colorectal Cancer.
Terminated·SSpanish Cooperative Group for the Treatment of Digestive Tumours (TTD)·Phase 2·NCT00531115·28 enrolled
Lenalidomide and Cetuximab in Treating Patients With Metastatic Colorectal Cancer
Terminated·—·Phase 1·NCT01126450·3 enrolled
Squamous Cell Carcinoma14 trials
Show 11 more trials
Study of Cetuximab in Squamous Cell Carcinoma of the Skin Expressing EGFR
Completed·—·Phase 2·NCT00240682·37 enrolled
Head and Neck Cancer13 trials
Show 10 more trials
Non-Small Cell Lung Cancer9 trials
Show 6 more trials
Cetuximab as Therapy for Recurrent Non-Small Cell Lung Cancer Patients Who Have Received Prior Therapy
Terminated·—·Phase 2·NCT00694603·56 enrolled
79 more indications
Gastric Cancer6 trials
Cetuximab, Paclitaxel, Carboplatin & Radiation for Esoph, Gastroesoph & Gastric Cancer
Completed·—·Phase 2·NCT00439608·60 enrolled
Show 3 more trials
Esophageal Cancer6 trials
Combination Chemotherapy, Radiation Therapy and Surgery for Esophageal Cancer
Completed·—·Phase 2·NCT00165490·19 enrolled
Show 3 more trials
Lung Cancer5 trials
Cetuximab and Vinorelbine in Elderly Subjects With Lung Cancer
Completed·—·Phase 2·NCT00165334·53 enrolled
Advanced Solid Tumors5 trials
Head and Neck Squamous Cell Carcinoma4 trials
Induction Chemotherapy4 trials
Treatment3 trials
Radiation Therapy3 trials
Metastatic Head and Neck Cancer3 trials
Advanced Head and Neck Cancer3 trials
Head and Neck Squamous Cell Cancer2 trials
Esophageal Carcinoma2 trials
Head and Neck2 trials
Locally Advanced2 trials
Pancreatic Cancer2 trials
Patients With Solid Tumors2 trials
Growth2 trials
Efficacy Analysis of Cetuximab Plus Irinotecan in Patients With Wild-type KRAS Without Regard to Epidermal Growth Factor Receptor (EGFR) Expressions
Completed·—·Phase 2·NCT00637091·40 enrolled
Small Cell Lung Cancer2 trials
Metastatic2 trials
Advanced or Metastatic Solid Tumors2 trials
Locally Advanced Head and Neck Cancer2 trials
Bevacizumab2 trials
Lohp, 5-Fu/Lv and Bevacizumab, Alternative With Cpt-11, 5-Fu/Lv and Cetuximab In Metastatic Crc
Terminated·—·Phase 2·NCT00755118·24 enrolled
Locally-advanced Rectal Cancer1 trial
Metastasis1 trial
Gefitinib1 trial
Refractory Solid Tumors1 trial
Glioma1 trial
Neoadjuvant Treatment1 trial
Thymic Carcinoma1 trial
Surgical1 trial
Concurrent Chemoradiotherapy1 trial
Patients With Advanced Solid Tumors1 trial
Oral Squamous Cell Carcinoma1 trial
mCRC1 trial
Safety of Cetuximab and Trifluridin Tipiracil as the Third-line Therapy in the RASwt mCRC
Unknown status·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Phase 1·NCT05155124·6 enrolled
Colon Cancer1 trial
Stage IV1 trial
Acute Lymphoblastic Leukemia1 trial
Cetuximab Rechallenge Study
Completed·—·Phase 2·NCT01832467·17 enrolled
Breast Cancer1 trial
Rectal Cancer1 trial
Metastatic Cancer1 trial
Cisplatin1 trial
A Study of Dasatinib, Cetuximab and Radiation With or Without Cisplatin in HNSCC
Terminated·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT00882583·22 enrolled
Breast Carcinoma1 trial
BRAF V600 Mutation1 trial
Neoadjuvant1 trial
Adenocarcinoma1 trial
Advanced/Metastatic Cancer1 trial
Maintenance Treatment1 trial
Cervical Cancer1 trial
Stage IV Rectal Cancer1 trial
Radiation Therapy, Irinotecan, and Cetuximab in Treating Patients Who Are Undergoing Surgery for Stage III or Stage IV Rectal Cancer
Unknown status·—·Phase 1·NCT00392470·20 enrolled
Safety and Efficacy1 trial
Gemcitabine1 trial
Oropharyngeal Cancer1 trial
Colorectal Carcinoma1 trial
Toxicity1 trial
Nasopharyngeal Carcinoma1 trial
KRAS G12C Mutation1 trial
Advanced Urothelial Cancer1 trial
Skin Cancer1 trial
Urothelial Cancer1 trial
B-cell acute lymphoblastic leukemia1 trial
Humanized CD19-Specific CAR T Cells for the Treatment of Patients With Positive Relapsed or Refractory CD19 Positive B-Cell Acute Lymphoblastic Leukemia
Recruiting·—·Phase 1·NCT06447987·24 enrolled
Cervical Carcinoma1 trial
Fallopian Tube Cancer1 trial
Unspecified2 trials
Regulatory
FDA Approval Timeline[4]
Feb 12, 2004
ERBITUX
BLA BLA125084
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Cetuximab. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]